Celia R Berkers

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7538321/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Targeting coenzyme Q10 synthesis overcomes bortezomib resistance in multiple myeloma. Molecular Omics, 2022, 18, 19-30.	1.4	8
2	Ascorbate kills breast cancer cells by rewiring metabolism via redox imbalance and energy crisis. Free Radical Biology and Medicine, 2021, 163, 196-209.	1.3	22
3	Anti-tumour immunity induces aberrant peptide presentation in melanoma. Nature, 2021, 590, 332-337.	13.7	81
4	Treatment with HIV-Protease Inhibitor Nelfinavir Identifies Membrane Lipid Composition and Fluidity as a Therapeutic Target in Advanced Multiple Myeloma. Cancer Research, 2021, 81, 4581-4593.	0.4	8
5	Omega-3 Fatty Acids DHA and EPA Reduce Bortezomib Resistance in Multiple Myeloma Cells by Promoting Glutathione Degradation. Cells, 2021, 10, 2287.	1.8	19
6	Oncogene-dependent sloppiness in mRNA translation. Molecular Cell, 2021, 81, 4709-4721.e9.	4.5	21
7	Stable human regulatory T cells switch to glycolysis following TNF receptor 2 costimulation. Nature Metabolism, 2020, 2, 1046-1061.	5.1	38
8	Nelfinavir Overcomes Proteasome Inhibitor Resistance in Multiple Myeloma By Modulating Membrane Lipid Bilayer Composition and Fluidity. Blood, 2020, 136, 11-11.	0.6	0
9	A fragment-like approach to PYCR1 inhibition. Bioorganic and Medicinal Chemistry Letters, 2019, 29, 2626-2631.	1.0	28
10	The Influence of Metabolism on Drug Response in Cancer. Frontiers in Oncology, 2018, 8, 500.	1.3	182
11	Proteasome Activation by Small Molecules. Cell Chemical Biology, 2017, 24, 725-736.e7.	2.5	113
12	Bortezomib resistance in multiple myeloma is associated with increased serine synthesis. Cancer & Metabolism, 2017, 5, 7.	2.4	115
13	Proteasome activity regulates CD8+ T lymphocyte metabolism and fate specification. Journal of Clinical Investigation, 2017, 127, 3609-3623.	3.9	35
14	Serine starvation induces stress and p53-dependent metabolic remodelling in cancer cells. Nature, 2013, 493, 542-546.	13.7	773
15	Fluorescence-Based Proteasome Activity Profiling. Methods in Molecular Biology, 2012, 803, 183-204.	0.4	18
16	Drug discovery and assay development in the ubiquitin–proteasome system. Biochemical Society Transactions, 2010, 38, 14-20.	1.6	19
17	Quantifying cross-tissue diversity in proteasome complexes by mass spectrometry. Molecular BioSystems, 2010, 6, 1450.	2.9	22
18	Molecular basis of bortezomib resistance: proteasome subunit β5 (PSMB5) gene mutation and overexpression of PSMB5 protein. Blood, 2008, 112, 2489-2499.	0.6	406

CELIA R BERKERS

#	ARTICLE	IF	CITATIONS
19	Profiling Proteasome Activity in Tissue with Fluorescent Probes. Molecular Pharmaceutics, 2007, 4, 739-748.	2.3	78
20	Distinct Dynamic Profiles for NPI-0052-And Bortezomib-Induced Apoptosis in Multiple Myeloma Blood, 2006, 108, 3396-3396.	0.6	2
21	Activity probe for in vivo profiling of the specificity of proteasome inhibitor bortezomib. Nature Methods, 2005, 2, 357-362.	9.0	230
22	Immunotherapeutic potential for ceramide-based activators of iNKT cells. Trends in Pharmacological Sciences, 2005, 26, 252-257.	4.0	88
23	In Vitro and In Vivo Proteasome Activity Profiles of Bortezomib and a Novel Proteasome Inhibitor NPI-0052 Blood, 2005, 106, 3363-3363.	0.6	1
24	TNFR2 Costimulation Differentially Impacts Regulatory and Conventional CD4+ T-Cell Metabolism. Frontiers in Immunology, 0, 13, .	2.2	7